Major Hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation

Article

关键词: ORAL ANTICOAGULANT-THERAPY;    BLEEDING COMPLICATIONS;    INTRACRANIAL HEMORRHAGE;    ANTITHROMBOTIC THERAPY;    MEDICARE BENEFICIARIES;    RANDOMIZED-TRIALS;    STROKE SEVERITY;    RISK-FACTORS;    INTENSITY;    OUTPATIENTS;   

DOI  :  10.1161/CIRCULATIONAHA.106.653048

来源: SCIE

【 摘 要 】

Background - Warfarin is effective in the prevention of stroke in atrial fibrillation but is under used in clinical care. Concerns exist that published rates of hemorrhage may not reflect real-world practice. Few patients >= 80 years of age were enrolled in trials, and studies of prevalent use largely reflect a warfarin-tolerant subset. We sought to define the tolerability of warfarin among an elderly inception cohort with atrial fibrillation. Methods and Results - Consecutive patients who started warfarin were identified from January 2001 to June 2003 and followed for 1 year. Patients had to be >= 65 years of age, have established care at the study institution, and have their warfarin managed on- site. Outcomes included major hemorrhage, time to termination of warfarin, and reason for discontinuation. Of 472 patients, 32% were >= 80 years of age, and 91% had >= 1 stroke risk factor. The cumulative incidence of major hemorrhage for patients >= 80 years of age was 13.1 per 100 person- years and 4.7 for those < 80 years of age (P = 0.009). The first 90 days of warfarin, age >= 80 years, and international normalized ratio (INR) >= 4.0 were associated with increased risk despite trial-level anticoagulation control. Within the first year, 26% of patients >= 80 years of age stopped taking warfarin. Perceived safety issues accounted for 81% of them. Rates of major hemorrhage and warfarin termination were highest among patients with CHADS(2) scores ( an acronym for congestive heart failure, hypertension, age >= 75, diabetes mellitus, and prior stroke or transient ischemic attack) of >= 3. Conclusions - Rates of hemorrhage derived from younger noninception cohorts underestimate the bleeding that occurs in practice. This finding coupled with the short-term tolerability of warfarin likely contributes to its underutilization. Stroke prevention among elderly patients with atrial fibrillation remains a challenging and pressing health concern.

【 授权许可】

Free